No article text was recorded for this version.
cost-effectiveness threshold
Version 1 of 182 papers117 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
- Blog: Cost‐effectiveness analysis of sintilimab plus <scp>IBI305</scp> versus sorafenib for unresectable hepatic cell carcinoma in China
- Blog: Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
- Blog: Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques
- Blog: Immune checkpoint inhibitors for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis
- Blog: Cost Effectiveness Analysis of CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma in China
- Blog: A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China
- Blog: Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
- Blog: Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
- Blog: Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment
- Blog: Health-related quality of life and financial toxicity in Chinese patients with multiple myeloma: a two-year real-world multicentre study
- Blog: Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
- Blog: Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
- Blog: Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock
- Blog: Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
- Blog: Grading Obamacare on the Fundamentals of Care Delivery
- Blog: Analysis of urban residents’ willingness to pay for packaging cancer screening and its influencing factors: a cross-sectional study in Sichuan, China
- Blog: Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions
- Blog: China's campaign against rare diseases
- Blog: Prevention of ulcer bleeding in high-risk patients: is the enthusiasm for COX-2 selective NSAIDs justified?
- Blog: Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients
- Blog: Acetaminophen or Tylenol? A Retrospective Analysis of Medication Digital Communication Practices
- Blog: A two-year mirror-image study of the effect of treatment with paliperidone and aripiprazole long-acting injections on need for inpatient care and home treatment intervention
- Blog: Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
- Blog: Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
- Blog: Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden
- Blog: Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: a case report
- Blog: ARIA Care Pathways 2019: Next-Generation Allergic Rhinitis Care and Allergen Immunotherapy in Malaysia
- Blog: Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease
- Blog: A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China
- Blog: Response to furmonertinib in a patient with non-Small cell lung cancer harboring HER2 exon 21 insertion mutation : a case report
- Blog: Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions
- Blog: Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
- Blog: Tracking progress towards equitable maternal and child health in Yunnan: a systematic assessment for the Health Programme for Poverty Alleviation in China during 2015–2020
- Blog: Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China
- Blog: A case report of effective treatment of intracranial atherosclerotic stenosis treated with the integration of traditional Chinese medicine and Western medicine
- Blog: Naturally Occurring PCSK9 Inhibitors: An Updated Review
- Blog: Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder
- Blog: Consensus Statement on Proton Therapy for Prostate Cancer
- Blog: Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy for Lung Cancer: protocol for a multicenter, double-blind and randomized controlled trial
- Blog: Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study
- Blog: The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
- Blog: Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma
- Blog: Potential impact of new oral anticoagulants on the management of atrial fibrillation‐related stroke in primary care
- Blog: Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
- Blog: Real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
- Blog: Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients
- Blog: A roadmap for personalized medicine: the findings of the IC2PerMed project
- Blog: B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China
- Blog: Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial
- Blog: A questionnaire-based study to comprehensively assess the status quo of rare disease patients in China
- Blog: Current Status and Future Development of Cell Transplantation Therapy for Periodontal Tissue Regeneration
- Blog: Der klinische Versorgungspfad zur multiprofessionellen Versorgung seltener Erkrankungen in der Pädiatrie – Ergebnisse aus dem Projekt TRANSLATE-NAMSE
- Blog: A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma
- Blog: A review of contemporary therapeutic strategies for the management of bladder cancer
- Blog: Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia
- Blog: Learning Cost-Effective and Interpretable Regimes for Treatment Recommendation
- Blog: Open Drug Knowledge Graph
- Blog: Activities and Roles of a Bioventure Company established by the Basic Research and Technology in Academia
- Blog: Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study
Showing 60 of 82 papers.
History & citation
Current · Permanent link
- This direction split from Bridging the Clinical Innovation and Economic Accessibility Gap (79% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_cost_effectiveness_threshold_24a34ab3,
title = {cost-effectiveness threshold},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/cost-effectiveness-threshold/rdr_24a34ab30ddc4b3fbb1ac82f610394ff},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 1, frozen text):
@misc{lacuna_cost_effectiveness_threshold_24a34ab3_v1,
title = {cost-effectiveness threshold},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/cost-effectiveness-threshold/rdr_24a34ab30ddc4b3fbb1ac82f610394ff/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}